Antenatal Magnesium Sulphate in High-Risk Preterm Patients
Key facts
- Phase
- Phase 3
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT07524972, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cairo University
- Trial code
- NCT07524972
- Record updated
- 13 April 2026
- Original description
The goal of this clinical trial is to evaluate whether antenatal magnesium sulphate reduces the risk of cerebral palsy in infants born to women at high risk of preterm birth. It will also assess the safety of magnesium sulfate for both the mother and the neonate. The main question it aims to answer is whether magnesium sulphate given before anticipated preterm delivery decreases the incidence of cerebral palsy without causing significant maternal or neonatal adverse effects. Researchers will compare magnesium sulphate with a placebo in women at high risk of preterm birth between 32 and 35 weeks of gestation. Participants will be randomly assigned to receive either intravenous magnesium sulphate or a placebo before delivery, and maternal and neonatal outcomes will be followed after birth, including neurodevelopmental assessment of the infant.Read full original descriptionShow less
Assessment of the Role of Antenatal Magnesium Sulphate in High-Risk Preterm Patients With Cerebral Palsy: a Randomized Clinical Trial
The goal of this clinical trial is to evaluate whether antenatal magnesium sulphate reduces the risk of cerebral palsy in infants born to women at high risk of preterm birth. It will also assess the safety of magnesium sulfate for both the mother and the neonate. The main question it aims to answer is whether magnesium sulphate given before anticipated preterm delivery decreases the incidence of cerebral palsy without causing significant maternal or neonatal adverse effects. Researchers will compare magnesium sulphate with a placebo in women at high risk of preterm birth between 32 and 35 weeks of gestation. Participants will be randomly assigned to receive either intravenous magnesium sulphate or a placebo before delivery, and maternal and neonatal outcomes will be followed after birth, including neurodevelopmental assessment of the infant.
Inclusion Criteria:; Pregnant women at high risk of preterm birth between 32 and 35 weeks of gestation; Birth is planned or expected within 24 hours; Singleton pregnancy; No contraindication to antenatal magnesium sulphate; Able to provide informed consent; Exclusion Criteria:; Higher-order multiple pregnancy; Received antenatal magnesium sulphate during the current pregnancy for hypertension or preeclampsia; Magnesium sulphate is required for treatment of preeclampsia; Second stage of labor; Respiratory rate less than 16 breaths per minute; Absent patellar reflexes; Urine output less than 100 mL in the previous 4 hours; Renal failure; Hypocalcemia; Myasthenia gravis; Magnesium sulphate infusion had to be stopped because of adverse effects.